While acknowledging AI's current impact on productivity (e.g., doubling trial recruitment speed), Gilead views its ultimate transformative potential in supporting complex strategic decisions. This includes using AI to synthesize disparate data (genomic, literature, RWE) to identify the optimal disease indications for a new drug target.

A common failure mode is sprinting forward with a molecule after seeing any signal in an animal model. Isaac Stoner advises overinvesting in robust in-vitro assay development first. This ensures a deep understanding of a molecule's functional activity on human biology, preventing costly translational failures later.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

In today's tightened market, a brilliant scientific platform isn't enough to secure investment. Investors have shifted to a product-focused lens, requiring founders to present a clear, detailed pathway from their idea to an approved drug. This includes defining the unmet medical need and outlining the proposed clinical trial design from day one.

Actis de-risks its drug development by using a platform where physicians can verify target engagement with imaging in early trials. This strategy confirms the drug is reaching the tumor, providing a crucial go/no-go signal long before expensive late-stage trials.

Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.

Gilead's acquisition strategy is not monolithic. It differentiates between acquiring foundational, long-duration platforms (like Kite's CAR-T) that kickstart a whole new area of R&D, and acquiring differentiated assets (like Arcelix's BCMA CAR-T) that strengthen an existing therapeutic area with a potentially transformative molecule.

The company intentionally makes its early research "harder in the short term" by using complex, long-term animal models. This counterintuitive strategy is designed to generate highly predictive data early, thereby reducing the massive financial risk and high failure rate of the later-stage clinical trials.

Gilead connects its diverse therapeutic areas—virology, oncology, and immunology—through a unified scientific principle. The immune system is the common thread: it must be activated to fight viruses and cancer but dampened in autoimmune diseases. This allows platform technologies like CAR-T to be leveraged across all three areas.